Yongchao Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yongchao Zhao has a total of 121 co-authors. Here are the top co-authors by number of shared publications:
- Bei Shi
Department of Cardiology, Affiliated Hospital of Zunyi Medical University
11 shared publications Zhimei Qiu
Department of Cardiology, Affiliated Hospital of Zunyi Medical University, Zunyi, China
7 shared publicationsNing Gu
Department of Cardiology, Affiliated Hospital of Zunyi Medical University, Zunyi, China, zmchospital.com.cn
6 shared publications- Junbo Ge
Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases
5 shared publications Chancui Deng
Department of Cardiology, Affiliated Hospital of Zunyi Medical University, Zunyi, China, zmchospital.com.cn
4 shared publications- Hao Lu
Department of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, China
4 shared publications
Latest Publications
- Top Cited Papers
- 29 January 2026
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (19) , 2308-2322
GLP-1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization
Background and Aims: Glucagon-like peptide-1 receptor agonists reduce heart failure (HF) risk in patients with diabetes or obesity. However, the extent to which this reduced risk is dependent on, or extends beyond, glucose control and weight reduction remains unclear. Methods: Two-sample cis-Mendelian randomization (MR) was used to assess causal effects of GLP-1R activation on HF risk, using glycated haemoglobin (HbA1c) reduction as a surrogate biomarker. The HF outcome was derived from a genome-wide association meta-analysis that included seven original studies and 1 665 481 participants. Primary analyses used inverse variance-weighted (IVW) and MR-robust adjusted profile score (MR-RAPS) methods. Mendelian randomization Bayesian model averaging was used to identify key mediators of the observed effects, while multivariable cis-MR with principal component generalized method of moments and network cis-MR were used to minimize the impact of confounders. Results: Genetically proxied GLP-1R activation was associated with reduced HF risk {IVW: odds ratio [OR] [95% confidence interval (CI)] .502 [.339, .743]; MR-RAPS: OR [95% CI] .492 [.320, .756]}. Mendelian randomization Bayesian model averaging identified body mass index (BMI) (marginal inclusion probability 67.2%) and Type 2 diabetes (T2D) (45.0%) as primary mediators. In multivariable cis-MR with principal component generalized method of moments, genetically predicted HbA1c levels from the GLP-1R locus remained significantly associated with HF risk after BMI adjustment, even in instances where BMI effects were non-significant [OR (95% CI) 1.663 (1.087, 2.544) at 99% variance threshold]. Network cis-MR confirmed persistent protection after adjusting for BMI [IVW: OR (95% CI) .587 (.394, .877); MR-RAPS: OR (95% CI) .577 (.375, .887)] or T2D [IVW: OR (95% CI) .508 (.343, .754); MR-RAPS: OR (95% CI) .499 (.327, .762)]. Conclusions: Glucagon-like peptide-1 receptor agonist-associated HF risk reduction is primarily mediated by BMI reduction rather than glucose control, but not fully explained by either. Residual effects after BMI and T2D adjustment suggest direct cardioprotective actions, supporting trials in non-obese, non-diabetic HF patients.
- 29 January 2026
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (19) , 2308-2322
Top Cited PapersGLP-1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization
Background and Aims: Glucagon-like peptide-1 receptor agonists reduce heart failure (HF) risk in patients with diabetes or obesity. However, the extent to which this reduced risk is dependent on, or extends beyond, glucose control and weight reduction remains unclear. Methods: Two-sample cis-Mendelian randomization (MR) was used to assess causal effects of GLP-1R activation on HF risk, using glycated haemoglobin (HbA1c) reduction as a surrogate biomarker. The HF outcome was derived from a genome-wide association meta-analysis that included seven original studies and 1 665 481 participants. Primary analyses used inverse variance-weighted (IVW) and MR-robust adjusted profile score (MR-RAPS) methods. Mendelian randomization Bayesian model averaging was used to identify key mediators of the observed effects, while multivariable cis-MR with principal component generalized method of moments and network cis-MR were used to minimize the impact of confounders. Results: Genetically proxied GLP-1R activation was associated with reduced HF risk {IVW: odds ratio [OR] [95% confidence interval (CI)] .502 [.339, .743]; MR-RAPS: OR [95% CI] .492 [.320, .756]}. Mendelian randomization Bayesian model averaging identified body mass index (BMI) (marginal inclusion probability 67.2%) and Type 2 diabetes (T2D) (45.0%) as primary mediators. In multivariable cis-MR with principal component generalized method of moments, genetically predicted HbA1c levels from the GLP-1R locus remained significantly associated with HF risk after BMI adjustment, even in instances where BMI effects were non-significant [OR (95% CI) 1.663 (1.087, 2.544) at 99% variance threshold]. Network cis-MR confirmed persistent protection after adjusting for BMI [IVW: OR (95% CI) .587 (.394, .877); MR-RAPS: OR (95% CI) .577 (.375, .887)] or T2D [IVW: OR (95% CI) .508 (.343, .754); MR-RAPS: OR (95% CI) .499 (.327, .762)]. Conclusions: Glucagon-like peptide-1 receptor agonist-associated HF risk reduction is primarily mediated by BMI reduction rather than glucose control, but not fully explained by either. Residual effects after BMI and T2D adjustment suggest direct cardioprotective actions, supporting trials in non-obese, non-diabetic HF patients.
- Open Access
- 1 January 2026
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 2026 (1) , e2279738
The Prognostic Value of Different Patterns of Neoatherosclerosis and Treatment Modality in Patients With Coronary In‐Stent Restenosis
Background: Neoatherosclerosis (NA) and treatment modality may influence outcomes in patients with in‐stent restenosis (ISR). This study evaluated the prognostic impact of different NA patterns and percutaneous coronary intervention (PCI) strategies guided by optical coherence tomography (OCT). Methods: We retrospectively analyzed 288 ISR lesions with OCT‐defined NA treated between January 2015 and December 2023. Lesions were classified as lipidic, calcified, or mixed NA. The primary endpoint was 1‐year target lesion failure (TLF), defined as a composite of cardiac death, nonfatal myocardial infarction, and clinically driven target lesion revascularization (CD‐TLR). Cox regression, interaction analysis, and propensity score matching (PSM) were performed. Results: No significant differences in TLF ( p = 0.420) or CD‐TLR ( p = 0.650) were observed among NA patterns. After adjustment for clinical and procedural covariates, DES reimplantation was associated with a lower risk of TLF (hazard ratio [HR] 0.390, 95% confidence interval [CI] 0.157–0.974; p = 0.044) and CD‐TLR (HR: 0.341, 95% CI: 0.114–0.925; p = 0.039) compared with DCB angioplasty. In patients with lipidic NA, a similar trend was observed (TLF: HR: 0.287; 95% CI: 0.097–0.849; p = 0.024; CD‐TLR: HR: 0.171; 95% CI: 0.039–0.750; p = 0.019). However, no significant interaction was observed between the NA pattern and treatment modality ( p for interaction = 0.543). Conclusion: No significant differences in clinical outcomes were observed across NA patterns. Although DES showed numerically favorable outcomes in lipidic NA, no significant interaction between NA pattern and treatment modality was detected. And these findings are hypothesis‐generating and may relate to the additional mechanical scaffolding and plaque sealing provided by DES in lipidic NA.
- 1 January 2026
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 2026 (1) , e2279738
Open AccessThe Prognostic Value of Different Patterns of Neoatherosclerosis and Treatment Modality in Patients With Coronary In‐Stent Restenosis
Background: Neoatherosclerosis (NA) and treatment modality may influence outcomes in patients with in‐stent restenosis (ISR). This study evaluated the prognostic impact of different NA patterns and percutaneous coronary intervention (PCI) strategies guided by optical coherence tomography (OCT). Methods: We retrospectively analyzed 288 ISR lesions with OCT‐defined NA treated between January 2015 and December 2023. Lesions were classified as lipidic, calcified, or mixed NA. The primary endpoint was 1‐year target lesion failure (TLF), defined as a composite of cardiac death, nonfatal myocardial infarction, and clinically driven target lesion revascularization (CD‐TLR). Cox regression, interaction analysis, and propensity score matching (PSM) were performed. Results: No significant differences in TLF ( p = 0.420) or CD‐TLR ( p = 0.650) were observed among NA patterns. After adjustment for clinical and procedural covariates, DES reimplantation was associated with a lower risk of TLF (hazard ratio [HR] 0.390, 95% confidence interval [CI] 0.157–0.974; p = 0.044) and CD‐TLR (HR: 0.341, 95% CI: 0.114–0.925; p = 0.039) compared with DCB angioplasty. In patients with lipidic NA, a similar trend was observed (TLF: HR: 0.287; 95% CI: 0.097–0.849; p = 0.024; CD‐TLR: HR: 0.171; 95% CI: 0.039–0.750; p = 0.019). However, no significant interaction was observed between the NA pattern and treatment modality ( p for interaction = 0.543). Conclusion: No significant differences in clinical outcomes were observed across NA patterns. Although DES showed numerically favorable outcomes in lipidic NA, no significant interaction between NA pattern and treatment modality was detected. And these findings are hypothesis‐generating and may relate to the additional mechanical scaffolding and plaque sealing provided by DES in lipidic NA.
- Open Access
- 6 October 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 11 (1) , 1-20
The role of cellular senescence in cardiovascular disease
The incidence of cardiovascular diseases rises significantly with age, making it one of the leading causes of death and disability worldwide, and cellular senescence plays a crucial role in this process. Cellular senescence constitutes a salient feature of organismal aging and stands as an independent risk factor for a range of cardiovascular diseases, encompassing hypertension, atherosclerosis, myocardial infarction, heart failure, and arrhythmia. This comprehensive review endeavors to comprehensively delineate the intricate regulatory mechanisms underlying cellular senescence and its attendant biological implications, while elucidating the profound implications of this process on the initiation and progression of cardiovascular diseases. Finally, we will delve into a spectrum of targeted interventions aimed at cellular senescence, specifically focusing on eliminating the accumulation of senescent cells during disease progression or inhibiting the inherent cellular senescence processes. Our ultimate goal is to mitigate or postpone the onset of diseases that are intricately linked to cellular senescence. A profound comprehension and rigorous investigation into the regulatory mechanisms of cellular senescence and their intricate interrelationships hold significant potential to furnish invaluable scientific evidence for the prevention and therapeutic strategies against cardiovascular diseases.
- 6 October 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 11 (1) , 1-20
Open AccessThe role of cellular senescence in cardiovascular disease
The incidence of cardiovascular diseases rises significantly with age, making it one of the leading causes of death and disability worldwide, and cellular senescence plays a crucial role in this process. Cellular senescence constitutes a salient feature of organismal aging and stands as an independent risk factor for a range of cardiovascular diseases, encompassing hypertension, atherosclerosis, myocardial infarction, heart failure, and arrhythmia. This comprehensive review endeavors to comprehensively delineate the intricate regulatory mechanisms underlying cellular senescence and its attendant biological implications, while elucidating the profound implications of this process on the initiation and progression of cardiovascular diseases. Finally, we will delve into a spectrum of targeted interventions aimed at cellular senescence, specifically focusing on eliminating the accumulation of senescent cells during disease progression or inhibiting the inherent cellular senescence processes. Our ultimate goal is to mitigate or postpone the onset of diseases that are intricately linked to cellular senescence. A profound comprehension and rigorous investigation into the regulatory mechanisms of cellular senescence and their intricate interrelationships hold significant potential to furnish invaluable scientific evidence for the prevention and therapeutic strategies against cardiovascular diseases.
- 5 September 2025
- p. 18980
Lactylation formation, gene regulation, biological functions, and clinical relevance.
Lactate, as an end-product of glycolysis, has been considered as a metabolic waste that participates in a few physiological functions. Recently, a novel study by Zhao's laboratory reported that lactate can serve as an epigenetic modification substrate, causing histone or nonhistone lysine residues to undergo lactylation, which then regulates gene transcription, translation, and protein function. Subsequent studies confirmed that lactylation plays an important role in a series of physiological and pathological processes, such as inflammation, cancer, and other biological processes. In this review, we summarize advanced achievements on the effects of lactylation in various diseases and potential treatment targets, providing a reference and direction for future research.
- 5 September 2025
- p. 18980
Lactylation formation, gene regulation, biological functions, and clinical relevance.
Lactate, as an end-product of glycolysis, has been considered as a metabolic waste that participates in a few physiological functions. Recently, a novel study by Zhao's laboratory reported that lactate can serve as an epigenetic modification substrate, causing histone or nonhistone lysine residues to undergo lactylation, which then regulates gene transcription, translation, and protein function. Subsequent studies confirmed that lactylation plays an important role in a series of physiological and pathological processes, such as inflammation, cancer, and other biological processes. In this review, we summarize advanced achievements on the effects of lactylation in various diseases and potential treatment targets, providing a reference and direction for future research.
- 5 August 2025
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
The role of systemic inflammation in mediating the association between red cell distribution width/albumin ratio and all-cause and cardiovascular mortality in cardiovascular disease patients with diabetes or prediabetes: insights from a large, population-based study
Introduction: The association between red cell distribution width-to-albumin ratio (RAR) and clinical outcomes in cardiovascular disease (CVD) patients with diabetes mellitus (DM) or pre-DM remains unclear, and its underlying mechanisms are not fully understood.Material and methods: This population-dependent prospective cohort study enrolled 3224 United States (U.S.) participants from the National Health and Nutrition Examination Survey (NHANES) (2001–2018) who had both CVD and either DM or pre-DM. Using the National Death Index data, the cohort’s mortality outcomes were tracked until December 31, 2019. Cox proportional hazard models and restricted cubic spline regressions were employed to investigate the associations between RAR and mortality outcomes. Notably, mediation analyses were performed to quantify the contribution of inflammatory markers, including neutrophils, monocytes, the neutrophil-to-lymphocyte ratio (NLR), and the systemic immune-inflammation index (SII), in the RAR-mortality relationship.Results: During a median 78-month follow-up, 1,223 deaths occurred (483 cardiovascular-related). Elevated RAR was significantly associated with increased all-cause mortality (hazard ratio = 1.43, 95% CI: 1.31–1.56) and cardiovascular mortality (1.44, 1.28–1.62). NLR and SII exhibited significant mediating effects (8.8–10.79% for all-cause; 9.58–11.99% for cardiovascular mortality).Conclusions: Elevated RAR was significantly associated with increased risk of all-cause mortality and cardiovascular mortality among patients with CVD and DM or pre-DM. Systemic inflammation significantly mediated these associations. RAR may serve as a practical prognostic marker in this high-risk population.
- 5 August 2025
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
The role of systemic inflammation in mediating the association between red cell distribution width/albumin ratio and all-cause and cardiovascular mortality in cardiovascular disease patients with diabetes or prediabetes: insights from a large, population-based study
Introduction: The association between red cell distribution width-to-albumin ratio (RAR) and clinical outcomes in cardiovascular disease (CVD) patients with diabetes mellitus (DM) or pre-DM remains unclear, and its underlying mechanisms are not fully understood.Material and methods: This population-dependent prospective cohort study enrolled 3224 United States (U.S.) participants from the National Health and Nutrition Examination Survey (NHANES) (2001–2018) who had both CVD and either DM or pre-DM. Using the National Death Index data, the cohort’s mortality outcomes were tracked until December 31, 2019. Cox proportional hazard models and restricted cubic spline regressions were employed to investigate the associations between RAR and mortality outcomes. Notably, mediation analyses were performed to quantify the contribution of inflammatory markers, including neutrophils, monocytes, the neutrophil-to-lymphocyte ratio (NLR), and the systemic immune-inflammation index (SII), in the RAR-mortality relationship.Results: During a median 78-month follow-up, 1,223 deaths occurred (483 cardiovascular-related). Elevated RAR was significantly associated with increased all-cause mortality (hazard ratio = 1.43, 95% CI: 1.31–1.56) and cardiovascular mortality (1.44, 1.28–1.62). NLR and SII exhibited significant mediating effects (8.8–10.79% for all-cause; 9.58–11.99% for cardiovascular mortality).Conclusions: Elevated RAR was significantly associated with increased risk of all-cause mortality and cardiovascular mortality among patients with CVD and DM or pre-DM. Systemic inflammation significantly mediated these associations. RAR may serve as a practical prognostic marker in this high-risk population.
- Open Access
- 2 July 2025
- Published by Ivyspring International Publisher in Theranostics
- Vol. 15 (15) , 7779-7801
Harnessing mRNA for heart health: a new era in cardiovascular treatment
MRNA serves as a versatile platform for the expression of paracrine factors, thereby promoting cardioprotection and regeneration. In recent years, mRNA and gene editing technologies have emerged as innovative tools for tackling complex diseases. Among these, mRNA therapeutics offer distinct advantages, including favorable immunological properties, strong safety profiles, and superior flexibility compared to conventional gene-based vaccines. Specifically, they can elicit a balanced immune response—encompassing both cellular and humoral immunity—without being limited by MHC haplotypes. Furthermore, mRNA therapy represents a particularly safe treatment modality. As a minimal and transient carrier of genetic information that does not integrate into the host genome, it significantly reduces the risk of insertional mutagenesis. Importantly, mRNA can be used to express virtually any protein without requiring changes to the production process, thus offering substantial flexibility in drug development. Collectively, these attributes highlight the great potential of mRNA as a next-generation therapeutic platform, particularly for cardiovascular diseases. This review summarizes recent progress in the development and application of mRNA-based drug formulations for cardiovascular therapy.
- 2 July 2025
- Published by Ivyspring International Publisher in Theranostics
- Vol. 15 (15) , 7779-7801
Open AccessHarnessing mRNA for heart health: a new era in cardiovascular treatment
MRNA serves as a versatile platform for the expression of paracrine factors, thereby promoting cardioprotection and regeneration. In recent years, mRNA and gene editing technologies have emerged as innovative tools for tackling complex diseases. Among these, mRNA therapeutics offer distinct advantages, including favorable immunological properties, strong safety profiles, and superior flexibility compared to conventional gene-based vaccines. Specifically, they can elicit a balanced immune response—encompassing both cellular and humoral immunity—without being limited by MHC haplotypes. Furthermore, mRNA therapy represents a particularly safe treatment modality. As a minimal and transient carrier of genetic information that does not integrate into the host genome, it significantly reduces the risk of insertional mutagenesis. Importantly, mRNA can be used to express virtually any protein without requiring changes to the production process, thus offering substantial flexibility in drug development. Collectively, these attributes highlight the great potential of mRNA as a next-generation therapeutic platform, particularly for cardiovascular diseases. This review summarizes recent progress in the development and application of mRNA-based drug formulations for cardiovascular therapy.
- Open Access
- 14 May 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-22
Relationship and prognostic value of the triglyceride-glucose index and optical coherence tomography-derived physiological index in patients with acute coronary syndrome
The optical flow ratio (OFR), derived from optical coherence tomography (OCT) images, serves as a physiological index, while the Triglyceride-Glucose Index (TyG) is an alternative measure of insulin resistance. Both indices are positively correlated with poor prognosis in patients with acute coronary syndrome (ACS), but the relationship between the TyG index, OFR, and their prognostic value remains unclear. We included ACS patients who underwent OCT between January 1, 2021, and March 31, 2023. The TyG index was calculated as Ln[fasting triglycerides (mg/dL) × fasting blood glucose (mg/dL)/2]. Patients were grouped into three categories (T1, T2, and T3) based on TyG tertiles. The primary endpoint was major adverse cardiovascular events (MACE). In our analysis, the T3 group showed a significantly higher incidence of MACE (P < 0.05), with a progressive decrease in vessel-level OFR observed as the TyG index increased, demonstrating a linear correlation (r = − 0.0146, P < 0.001). The restricted cubic splines (RCS) model revealed a nonlinear relationship between the TyG index and the likelihood of MACE (P for nonlinear < 0.021). Additionally, the cumulative incidence of MACE was significantly higher in patients with a higher TyG index (all Log-rank P < 0.001).These findings suggest a nonlinear relationship between the TyG index and MACE, and a linear association between the TyG index and vessel-level OFR. The combination of the TyG index and OFR significantly improved discriminatory ability (c-index: 0.720 vs. 0.757; P < 0.001) and reclassification ability (net reclassification index [NRI]: 0.373; integrated discrimination improvement [IDI]: 0.031; P < 0.0001) for predicting MACE compared to vessel-level OFR alone. This combination effectively identifies high-risk ACS patients.
- 14 May 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-22
Open AccessRelationship and prognostic value of the triglyceride-glucose index and optical coherence tomography-derived physiological index in patients with acute coronary syndrome
The optical flow ratio (OFR), derived from optical coherence tomography (OCT) images, serves as a physiological index, while the Triglyceride-Glucose Index (TyG) is an alternative measure of insulin resistance. Both indices are positively correlated with poor prognosis in patients with acute coronary syndrome (ACS), but the relationship between the TyG index, OFR, and their prognostic value remains unclear. We included ACS patients who underwent OCT between January 1, 2021, and March 31, 2023. The TyG index was calculated as Ln[fasting triglycerides (mg/dL) × fasting blood glucose (mg/dL)/2]. Patients were grouped into three categories (T1, T2, and T3) based on TyG tertiles. The primary endpoint was major adverse cardiovascular events (MACE). In our analysis, the T3 group showed a significantly higher incidence of MACE (P < 0.05), with a progressive decrease in vessel-level OFR observed as the TyG index increased, demonstrating a linear correlation (r = − 0.0146, P < 0.001). The restricted cubic splines (RCS) model revealed a nonlinear relationship between the TyG index and the likelihood of MACE (P for nonlinear < 0.021). Additionally, the cumulative incidence of MACE was significantly higher in patients with a higher TyG index (all Log-rank P < 0.001).These findings suggest a nonlinear relationship between the TyG index and MACE, and a linear association between the TyG index and vessel-level OFR. The combination of the TyG index and OFR significantly improved discriminatory ability (c-index: 0.720 vs. 0.757; P < 0.001) and reclassification ability (net reclassification index [NRI]: 0.373; integrated discrimination improvement [IDI]: 0.031; P < 0.0001) for predicting MACE compared to vessel-level OFR alone. This combination effectively identifies high-risk ACS patients.
- 10 January 2025
- Published by Elsevier in Science Bulletin
- Vol. 70 (6) , 798-800
Enhancing panvascular medicine: unveiling the nexus of pan-cardio-oncology and expanding therapeutic frontiers
- 10 January 2025
- Published by Elsevier in Science Bulletin
- Vol. 70 (6) , 798-800
Enhancing panvascular medicine: unveiling the nexus of pan-cardio-oncology and expanding therapeutic frontiers
- 1 November 2024
- Published by Elsevier in Life Sciences
- Vol. 358, 123199
Nanomedicine in cardiology: Precision drug delivery for enhanced patient outcomes
- 1 November 2024
- Published by Elsevier in Life Sciences
- Vol. 358, 123199
Nanomedicine in cardiology: Precision drug delivery for enhanced patient outcomes